Search PubMed⌕ Search

Biomedical subjects

G Chappuis

Publications and source records attributed to G Chappuis.

63 records · Page 4Linked to original sources
PubMed1975

Live and killed virus vaccines: their use against the respiratory diseases of cattle.

The respiratory diseases of cattle are due to a combination of different factors among which figures a viral infection. The antiviral vaccination, perfectly possible owing to associated killed vaccines and live virus, is thus a very important element which must enter into every general plan of prophylaxis. Moreover, these plans will concern bacterial infections, conditions of rearing, etc. We have demonstrated that it is possible to produce good immunity in calves and sheep using a trivalent killed vaccine (parainfluenza 3, adenovirus 3 and reovirus 1). Possible interference with antibodies of maternal origin makes the multiplication of vaccine injections desirable.

Adenoviridae↗
PubMedDate not supplied

Neonatal immunity and immunisation in early age: lessons from veterinary medicine.

The objective of this paper is to review adaptive immunity of young animals using examples from my own experience and from the literature. Trials carried out by us with a modified live and inactivated canine parvovirus vaccine in newborn puppies provide evidence of the immune capacity of these puppies. With regard to transfer of immunity from mother to offspring, there is a role for transplacental and colostral immunity. Examples of passive protection of young animals against different infections include passive protection of kittens against the feline immunodeficiency virus. However, passive immunity, though very useful at an early age, varies in duration and makes implementation of standard vaccination schedules difficult. Other experiments demonstrate that, under certain conditions, it is possible to overcome residual maternally-derived antibodies and to induce post-vaccinal immunity.

Animals↗
PubMedDate not supplied

Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine.

Rabies infection of domestic and wild animals is a serious problem throughout the world. The major disease vector in Europe is the red fox (Vulpes vulpes) and rabies control has focused on vaccinating and/or culling foxes. Culling has not been effective, and the distribution of five vaccine baits is the only appropriate method for the vaccination of wild foxes. Although some European countries have conducted field vaccination campaigns using attenuated rabies virus strains, their use has not been extensively approved because they retain pathogenicity for rodents and can revert to virulence. These strains cannot be used in North America because they are pathogenic for the striped skunk (Mephitis mephitis) and are ineffective in the raccoon (Procyon lotor). We have constructed a recombinant vaccinia virus, VVTGgRAB, expressing the surface glycoprotein (G) of rabies virus (ERA strain). The recombinant was a highly effective vaccine in experimental animals, in captive foxes and in raccoons. We report here the results of a large-scale campaign of fox vaccination in a 2,200 km2 region of southern Belgium, an area in which rabies is prevalent. After distribution, 81% of foxes inspected were positive for tetracycline, a biomarker included in the vaccine bait and, other than one rabid fox detected close to the periphery of the treated area, no case of rabies, either in foxes or in domestic livestock, has been reported in the area.

Animals↗
PubMedDate not supplied

Mass vaccination campaign against rabies: are dogs correctly protected? The Peruvian experience.

In a mass vaccination campaign conducted in Peru in March 1985, 270,000 dogs (65% of the estimated dog population) were vaccinated over the course of 1 month with an inactivated tissue culture vaccine. Since that time no human rabies cases have been reported; in addition, the number of animal rabies cases has declined to only three from a previous mean of 292 cases per year since 1980. A serologic survey was also done to determine the immune response among randomly selected vaccinated dogs, with titers determined 3, 6, 9, and 12 months after vaccination. Twelve months after vaccination, 97% of the dogs had a rabies neutralizing antibody titer of greater than or equal to 0.5 IU/mL, and 87% had a titer of greater than or equal to 1.0 IU/mL. Thus, this tissue culture rabies vaccine given under field conditions induced antibodies that lasted for at least 1 year in 97% of vaccinated dogs.

Animals↗